"Spikevax/Booster Sales Expectations are Largely Reflected in the Stock" - Needham & Company Maintains Moderna (MRNA) at Hold
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Hold rating on Moderna (NASDAQ: MRNA), following the company's Annual Science Day.The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
